Aceragen's delayed Form 10-Q filing has led to a Nasdaq notice, which may cause concern among investors and lead to a negative impact on the stock price in the short term. The notice indicates that the company is not in compliance with Nasdaq's listing requirements, which could result in further regulatory actions if not resolved.